- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07290478
Encouraging Older Adults and Adults With Serious Illness to Designate a Health Care Proxy
April 17, 2026 updated by: Mireille Jacobson, University of Southern California
A Randomized Trial to Encourage Older Adults and Adults With Serious Illness to Designate a Health Care Proxy
This study is a Stage III randomized trial to encourage patients in advance of a health care appointment to designate a healthcare proxy.
Patients will be randomly assigned to receive a mailer containing information about designating a healthcare proxy, or to not receive any mailer.
For patients assigned to receive a mailer, the mailer will differ by the presence or absence of a patient pre-commitment prompt, and contain a personalized provider request or a generic health system request.
The work will evaluate the randomized trial and identify factors that predict intervention effectiveness.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
10000
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mireille Jacobson, PhD
- Phone Number: 213-821-8296
- Email: mireillj@usc.edu
Study Contact Backup
- Name: Tara K Knight, PhD
- Email: knight@usc.edu
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- No EHR-documented healthcare proxy at enrollment
- Age ≥ 55 years OR age ≥ 18 years and listed in the health system's cancer, CHF, or CKD registries
Exclusion Criteria:
- None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: No Mailer Control
Patients will not receive a mailer.
|
|
|
Experimental: Provider Mailer with a Pre-commitment Prompt
Patients will receive a mailer containing a pre-commitment prompt to bring in a form listing their healthcare proxy to their next primary care visit.
The mailer will be sent from and signed by their primary care provider.
|
Patient mailers will ask the patient to name a healthcare proxy at their next primary care visit.
Patient mailers will contain a box that asks the patient to bring a form with their choice for a healthcare proxy to their next primary care visit.
Patient mailers will be sent from and signed by the patient's provider for their next scheduled primary care visit.
|
|
Experimental: Health System Mailer with a Pre-commitment Prompt
Patients will receive a mailer containing a pre-commitment prompt to bring in a form listing their healthcare proxy to their next primary care visit.
The mailer will be sent from and signed by the health system
|
Patient mailers will ask the patient to name a healthcare proxy at their next primary care visit.
Patient mailers will contain a box that asks the patient to bring a form with their choice for a healthcare proxy to their next primary care visit.
|
|
Experimental: Provider Mailer without a Pre-commitment Prompt
Patients will receive a mailer, but it will not contain a pre-commitment prompt to bring in a form listing their healthcare proxy to their next primary care visit.
The mailer will be sent from and signed by the patient's provider.
|
Patient mailers will ask the patient to name a healthcare proxy at their next primary care visit.
Patient mailers will be sent from and signed by the patient's provider for their next scheduled primary care visit.
|
|
Experimental: Health System Mailer without a Pre-commitment Prompt
Patients will receive a mailer, but it will not contain a pre-commitment prompt to bring in a form listing their healthcare proxy to their next primary care visit.
The mailer will be sent from and signed by the health system.
|
Patient mailers will ask the patient to name a healthcare proxy at their next primary care visit.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of patients with EHR-documented healthcare proxy
Time Frame: Within 30 days of the patient's first scheduled primary care visit
|
Documentation in the electronic health record of a healthcare proxy
|
Within 30 days of the patient's first scheduled primary care visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of patients that attended scheduled visit
Time Frame: On the date of the patient's first scheduled primary care visit
|
Patient attended the scheduled primary care visit
|
On the date of the patient's first scheduled primary care visit
|
|
Proportion of patients with EHR-documented healthcare proxy within 90 days
Time Frame: Within 90 days of the patient's first scheduled primary care visit
|
Documentation in the electronic health record of a healthcare proxy
|
Within 90 days of the patient's first scheduled primary care visit
|
|
Proportion of patients with primary care visit within 90 days
Time Frame: Within 90 days of the patient's first scheduled primary care visit
|
Patient attended a primary care visit
|
Within 90 days of the patient's first scheduled primary care visit
|
|
Proportion of patients with legal advance care planning documentation
Time Frame: Within 30 days of the patient's first scheduled primary care visit
|
Documentation in the electronic health record of any legal advance care planning document, including an advance directive or power of attorney
|
Within 30 days of the patient's first scheduled primary care visit
|
|
Proportion of patients with legal advance care planning documentation within 90 days
Time Frame: Within 90 days of the patient's first scheduled primary care visit
|
Documentation in the electronic health record of any legal advance care planning document, including an advance directive or power of attorney
|
Within 90 days of the patient's first scheduled primary care visit
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Mireille Jacobson, PhD, University of Southern California
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 1, 2026
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
August 31, 2027
Study Registration Dates
First Submitted
December 12, 2025
First Submitted That Met QC Criteria
December 17, 2025
First Posted (Actual)
December 18, 2025
Study Record Updates
Last Update Posted (Actual)
April 22, 2026
Last Update Submitted That Met QC Criteria
April 17, 2026
Last Verified
April 1, 2026
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- UP-23-01203
- P30AG024968 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
De-identified IPD used for results publication may be shared upon request and with approval by the health system.
IPD Sharing Time Frame
IPD will be available for one year after the study publication date.
IPD Sharing Access Criteria
IPD access criteria will be governed by a data use agreement signed by both parties.
IPD Sharing Supporting Information Type
- SAP
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Designating a Healthcare Proxy
-
Virginia Commonwealth UniversityCompletedEffectiveness of Antimicrobial Impregnated Scrubs in a Healthcare SettingUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompletedA Healthcare Professional, a Patient or Caregiver in the Radiation Oncology Department at the University of PennsylvaniaUnited States
-
SingHealth PolyclinicsCompletedAdvanced Medical Directive, a Legal Document Signed in Advance to State Healthcare PreferencesSingapore
-
University Hospital, BordeauxUniversity of BordeauxCompletedEvaluation of a National Health Information Technology-based Program to Improve Healthcare Coordination and Access to InformationFrance
-
Assistance Publique - Hôpitaux de ParisCompletedAlzheimer's Disease | Capacity to Consent to Treatment | Capacity to Vote | Capacity to Design a ProxyFrance
-
University of California, San FranciscoUniversity of California, DavisNot yet recruitingParticipants Must be Women Aged 25 Years or Older | Participants Should Have no Self-reported History of Heart Disease or Stroke | Participants Should Have no Terminal Illness or Diagnosed Cognitive Impairment, Including Alzheimer's Disease | Participants Should Not be a Healthcare Professionals... and other conditionsUnited States
-
University of Wisconsin, MadisonCompletedHealthcare Worker, Hepatitis B Vaccine, NonresponderUnited States
-
Centre Hospitalier le MansNot yet recruitingIntubated Patient Requiring a Gastric TubeFrance
-
Daniel BenjaminEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedHeart Failure | Epilepsy | Pain | Pneumonia | Sepsis | Inflammation | Hypertension | Chronic Kidney Diseases | Hemophilia | Schizophrenia | Central Nervous System Infections | Nosocomial Pneumonia | Insomnia | Anxiety | Bipolar Disorder | Neutropenia | Staphylococcal Infections | Bradycardia | Seizures | Urinary Tract Infections | Pulmonary... and other conditionsUnited States, Canada, United Kingdom, Israel, Singapore
Clinical Trials on Mailer
-
NYU Langone HealthCompleted
-
National Opinion Research CenterUniversity of Alabama at Birmingham; Icahn School of Medicine at Mount Sinai; Centers for Disease Control and Prevention and other collaboratorsCompletedHepatitis C | Chronic Hepatitis CUnited States
-
Geisinger ClinicCompletedHealth Promotion | Prevention | Risk Reduction BehaviorUnited States
-
University Medical Center GroningenCompletedCovid19 | Chronic Kidney Diseases | SARS-CoV InfectionNetherlands
-
National University Hospital, SingaporeEnrolling by invitationThis Study Evaluates Interventions to Increase Surveillance Mammography Uptake for Early Breast Cancer Detection Among Singaporean WomenSingapore